Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given a consensus rating of “Buy” by the eight brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $43.17.

ORKA has been the topic of a number of research reports. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, December 20th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC purchased a new position in Oruka Therapeutics in the third quarter worth approximately $114,763,000. RTW Investments LP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $45,359,000. Franklin Resources Inc. acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $17,661,000. Braidwell LP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at $12,640,000. Finally, Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $12,614,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Shares of Oruka Therapeutics stock opened at $12.47 on Tuesday. The firm has a market cap of $436.45 million, a price-to-earnings ratio of -1.99 and a beta of 0.81. Oruka Therapeutics has a 12-month low of $11.95 and a 12-month high of $53.88. The company’s 50 day moving average is $19.57.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.